×

Ehave to take Curedash platform into the Ketamine home delivery service for Ketamine clinics


MIAMI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced KetaDASH www.ketadash.com, an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine.

Ehave, Inc. has entered into an asset purchase agreement to acquire the tangible and intangible assets of a San Diego, CA based IV therapy service CureDash www.curedash.com. CureDash currently operates an IV delivery platform that will become the backbone of KetaDash. KetaDASH will provide the platform for medical practitioners to administer Ketamine intravenously to patients at home. Ketamine is currently used to help ease pain and allows sedatives to be effective at lower doses, lessening the amount of potentially addictive pain medication required after certain medical procedures. Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression.

The KetaDASH platform will include software, staffing, protocols, and equipment. Ehave has designed a smart and intuitive dashboard for KetaDash from where the clients and the associated nurses can get detailed insight on how the Ketamine therapy is working. Patients will be able to create a profile, check availability of administering nurses, and schedule appointments.

According to Multidisciplinary Association for Psychedelic Studies, a non-profit research and educational organization, "There has been a recent explosion of interest in ketamine, a synthetic chemical with powerful antidepressant and visionary properties." Ketamine was originally developed in the 1960s as a short-acting surgical anesthetic, however, it is emerging as a therapy for treatment-resistant depression, and showing benefits in the treatment of both unipolar and bipolar depression. A recent article on RealMoney.com said, "While there is a lot of fuss about a potential legal market for psilocybin, ketamine is currently where the money is for alternative plant medicine companies. Ketamine clinics are springing up across the country as the total addressable market is estimated to be roughly $16.2 billion."

"Forward thinking Technology is going to be the next wave of how we receive healthcare," said Alfred Farrington II, Chief Information Officer of Ehave.

Victor S. Dorodny, MD,ND,PHD,MPH (www.DrDorodny.com), Medical Advisor to Ehave, said, “Ketamine, a widely used anesthetic medication, is now being used to treat depression, suicidality, chronic pain, migraines, OCD and even some PTSD symptoms. For many, this breakthrough treatment represents a powerful opportunity to manage their mental health challenges. KetaDash will allow the patients who are prescribed Ketamine to receive required treatments in the safety and comfort of their homes.”

“Our continued dedication and commitment to mental health has expanded into both telehealth and psychedelics over the past year. As 2020 draws to a close, healthcare providers will need to retool their telehealth efforts in order to prepare for the growing mental health crisis," said Ben Kaplan, CEO of Ehave, Inc. Mr. Kaplan continued, "KetaDASH will not only provide potentially lifesaving Ketamine infusion therapy for the treatment of psychiatric disorders, such as major depressive disorder, bipolar disorder, and post-traumatic stress disorder, it also provides Ehave the opportunity to build a revenue producing platform."

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company diligently posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046

Email: erelationsgroup@gmail.com 


© Copyright 2016-2020 Ehave, Inc. All Right Reserved